Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nab-paclitaxel + carboplatin + camrelizumab
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
nab-paclitaxel + carboplatin + camrelizumab is a combination regimen used primarily in oncology, consisting of three agents with distinct mechanisms. Nab-paclitaxel is a nanoparticle albumin-bound formulation of paclitaxel, a microtubule inhibitor that disrupts cell division. Carboplatin is a platinum-based chemotherapeutic agent that induces DNA crosslinking and apoptosis. Camrelizumab is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor to enhance T-cell mediated antitumor responses. This combination has been investigated as neoadjuvant or first-line therapy for several cancers, including extensive-stage small cell lung cancer (ES-SCLC), non-small cell lung cancer (NSCLC), and esophageal squamous cell carcinoma (ESCC). Clinical studies have shown promising efficacy and manageable safety profiles in these indications[1][2][3][5].
- Brand names
- AiRuiKa (for camrelizumab)
- Other names
- nanoparticle albumin-bound paclitaxel + carboplatin + camrelizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on nab-paclitaxel + carboplatin + camrelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nab-paclitaxel + carboplatin + camrelizumab.